Stock Price
18.75
Daily Change
0.61 3.36%
Monthly
-2.60%
Yearly
-21.94%
Q4 Forecast
18.33

EPS Reference Time Actual Consensus Previous
2026-11-04 FY2026Q3 PM 0.31 0.13 0.42
2026-08-04 FY2026Q2 PM 0.18 0.06 0.16
2026-05-06 FY2026Q1 PM 0.02 0.07 0.11
2026-02-25 FY2025Q4 PM 1.60 0.14 0.86
2025-11-05 FY2025Q3 PM 0.42 0.14 0.20



Peers Price Chg Day Year Date
Eisai 5,280.00 94.00 1.81% 12.94% Nov/16
Acadia Pharmaceuticals 18.75 0.61 3.36% -21.94% Nov/13
ALKERMES 47.03 0.05 0.11% 61.95% Nov/13
Alnylam Pharmaceuticals 165.04 8.39 5.36% -63.26% Nov/13
Biogen 253.40 2.92 1.17% 51.24% Nov/13
BioMarin Pharmaceutical 57.23 0.53 0.93% 4.57% Nov/13
Bristol-Myers Squibb 63.43 1.11 1.78% 35.97% Nov/13
Cara Therapeutics 1.18 0.03 2.16% -70.72% Nov/13
Corcept Therapeutics 72.94 -0.77 -1.04% -3.44% Nov/13
Cytokinetics 56.13 -0.03 -0.05% -15.52% Nov/13

Indexes Price Day Year Date
USND 25136 -229.82 -0.91% 9.76% Nov/13
US Index 2000 2790 -8.57 -0.31% 16.84% Nov/13

Acadia Pharmaceuticals traded at $18.75 this Friday November 13th, increasing $0.61 or 3.36 percent since the previous trading session. Looking back, over the last four weeks, Acadia Pharmaceuticals gained 2.60 percent. Over the last 12 months, its price fell by 21.94 percent. Looking ahead, we forecast Acadia Pharmaceuticals to be priced at 18.33 by the end of this quarter and at 17.12 in one year, according to Trading Economics global macro models projections and analysts expectations.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).